Detalus Advisors LLC Buys 11,526 Shares of Danaher Corporation $DHR

Detalus Advisors LLC lifted its stake in Danaher Corporation (NYSE:DHR) by 975.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,708 shares of the conglomerate’s stock after purchasing an additional 11,526 shares during the period. Detalus Advisors LLC’s holdings in Danaher were worth $2,815,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Danaher during the 2nd quarter worth $10,492,520,000. Wellington Management Group LLP boosted its position in Danaher by 10.4% in the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock valued at $3,108,031,000 after buying an additional 1,542,310 shares during the last quarter. Jupiter Topco LLC acquired a new stake in shares of Danaher in the 2nd quarter valued at $1,456,317,000. Generation Investment Management LLP acquired a new stake in shares of Danaher in the 2nd quarter valued at $1,287,949,000. Finally, Bank of America Corp DE bought a new stake in shares of Danaher during the second quarter worth $993,846,000. Institutional investors own 79.05% of the company’s stock.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 price target on shares of Danaher in a research note on Wednesday, July 22nd. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a report on Saturday, October 10th. Morgan Stanley lifted their price objective on Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research report on Monday. Wells Fargo & Company dropped their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Finally, Weiss Ratings raised Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average target price of $235.41.

Danaher Trading Up 3.0%

Shares of NYSE DHR opened at $231.52 on Friday. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The firm has a market capitalization of $162.76 billion, a P/E ratio of 41.12, a P/E/G ratio of 2.82 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company’s 50 day simple moving average is $213.55 and its 200 day simple moving average is $195.74.

Danaher (NYSE:DHR) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the previous year, the business earned $0.77 EPS. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. On average, analysts predict that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is currently 28.42%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.